Connor McDermott is a Vice President at Northpond Ventures where he evaluates and supports biotechnology companies. Connor joined Northpond in 2019 as a member of the investment team and has conducted diligence on 16 closed investments in biotherapeutics companies. In addition to Triumvira, Connor is a Board Director for Transition Bio and is a Board Observer for Aro Biotherapeutics, Faro Health, Garuda Therapeutics, Opna Bio, Totus Medicines, and Walking Fish Therapeutics. Previously, Connor worked in Investment Banking at Leerink Partners, a life science-focused investment bank, where he supported biotechnology companies on business development, IPOs, and M&A transactions. Connor earned a B.A. in Biology and a B.A. in Economics from Brown University.